Skip to content

The effect of the dietary antioxidant supplements lutein and zeaxanthin on retinal macular pigment optical density

Macular pigment response to supplemental lutein and zeaxanthin: a twin heritability study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN55089134
Enrollment
322
Registered
2012-02-10
Start date
2004-03-07
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration (AMD) Eye Diseases Degeneration of macula

Interventions

All participants asked to take daily macular pigment supplement with food, ?Macuvite? (Springfield®), consisting of 18mg lutein (in its free form) and 2.4mg zeaxanthin (derived from marigold flowers a

Sponsors

Guy's & St Thomas' NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Healthy female volunteers, aged 16-50 2. Twin pairs enrolled on TwinsUK adult registry held at St Thomas? Hospital London (aim to recruit 80 monozygotic and 80 dizygotic pairs)

Exclusion criteria

Exclusion criteria: 1. Ocular pathology 2. Gastrointestinal disease

Design outcomes

Primary

MeasureTime frame
Heritability of response to macular pigment supplement, measured using: 1. Reverse phase high performance liquid chromatography to measure serum carotenoid levels at baseline and three months 2. Heterochromatic flicker photometry (HFP) and 2-wavelength fundus autofluorescence (AF) to measure macular pigment optical density (MPOD) at baseline, three months and six months 3. Maximum likelihood modelling using Mx programme to estimate heritability of MP response to supplementation

Secondary

MeasureTime frame
1. Relationship between central retinal thickness and MPOD, measured using: 1.1. Optical coherence tomography to measure retinal thickness 1.2. HFP and AF to measure MPOD 2. Heritability of MP in the healthy eye, measured using: 2.1. HFP and AF to measure MPOD 2.2. Maximum likelihood modelling using Mx programme to estimate heritability of MPOD

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026